Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints

E. Farfour , N. Degand , E. Riverain , V. Fihman , C. Le Brun , G. Péan de Ponfilly , A. Muggeo , A. Jousset , C. Piau , P. Lesprit
{"title":"Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints","authors":"E. Farfour ,&nbsp;N. Degand ,&nbsp;E. Riverain ,&nbsp;V. Fihman ,&nbsp;C. Le Brun ,&nbsp;G. Péan de Ponfilly ,&nbsp;A. Muggeo ,&nbsp;A. Jousset ,&nbsp;C. Piau ,&nbsp;P. Lesprit","doi":"10.1016/j.medmal.2020.07.003","DOIUrl":null,"url":null,"abstract":"<div><p>The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24<!--> <!-->mm versus 19<!--> <!-->mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, <em>P</em> <!-->&lt;<!--> <!-->0.01) and reached 2.8% and 86.5% in <em>E. coli</em> and <em>K. pneumoniae</em>, respectively. French guidelines for the management of community-acquired UTI remain appropriate. The accuracy of the methods for routine fosfomycin susceptibility testing should be assessed. The role of fosfomycin in the treatment of documented CA-UTI due to Enterobacterales other than <em>E. coli</em> should be evaluated considering its rate of resistance and recent data reporting low accuracy.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 7","pages":"Pages 611-616"},"PeriodicalIF":5.0000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.003","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine et maladies infectieuses","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0399077X20306442","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5

Abstract

The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24 mm versus 19 mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, P < 0.01) and reached 2.8% and 86.5% in E. coli and K. pneumoniae, respectively. French guidelines for the management of community-acquired UTI remain appropriate. The accuracy of the methods for routine fosfomycin susceptibility testing should be assessed. The role of fosfomycin in the treatment of documented CA-UTI due to Enterobacterales other than E. coli should be evaluated considering its rate of resistance and recent data reporting low accuracy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
磷霉素,从易感性到耐药性:新指南对断点的影响
在2019年CA-SFM/EUCAST指南v2中,使用椎间盘扩散法(DDM)的磷霉素断点发生了变化(24 mm vs 19 mm)。我们评估了其对急诊科尿液样本中肠杆菌分类的影响。采用DDM法和BMD法分别检测了7749株和2348株菌株。具有19毫米断点的DDM与BMD一致。采用24mm断点,肠杆菌对磷霉素的总体耐药率增加了3倍(5.6% vs 18.1%, P <0.01),大肠杆菌和肺炎克雷伯菌分别为2.8%和86.5%。法国社区获得性尿路感染管理指南仍然适用。应评估常规磷霉素药敏试验方法的准确性。考虑到磷霉素的耐药率和最近报道的准确性较低的数据,应该评估磷霉素在治疗大肠杆菌以外的肠杆菌引起的CA-UTI中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medecine et maladies infectieuses
Medecine et maladies infectieuses 医学-传染病学
CiteScore
1.10
自引率
0.00%
发文量
0
审稿时长
10.7 weeks
期刊介绍: L''organe d''expression de la Société de Pathologie Infectieuse de Langue Française (SPILF). Médecine et Maladies Infectieuses is the official publication of the Société de Pathologie Infectieuse de Langue Française (SPILF). Médecine et Maladies Infectieuses is indexed in the major databases: Medline, Web of Science/Clarivate and Scopus. The journal publishes scientific /research articles, general reviews, short communications and letters, in both English and French. The journal welcomes submissions on the various aspects of infectious pathologies and pathogenic agents. Médecine et Maladies Infectieuses focuses on clinical therapeutics, nosocomial infections, biology, prevention, as well as epidemiology and therapeutics.
期刊最新文献
Editorial board Implant retention and high rate of treatment failure in hematogenous acute knee and hip prosthetic joint infections PK/PD targets of amikacin and gentamicin in ICU patients Flu vaccine coverage for recommended populations in France Antimicrobial resistance in N’Djamena (Chad): Four-year experience of the French Forward Medical and Surgical Team engaged in the “Barkhane Operation”
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1